APP and Cognitive impairment: Overall, APP/PS1 model demonstrates that AAVT42-mediated delivery of BDNF into the hippocampus promotes neuroprotection against Aβ-induced neurotoxicity and strengthens dendritic structure during AD pathogenesis, thus alleviating cognitive impairment.